<DOC>
	<DOC>NCT01341132</DOC>
	<brief_summary>This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).</brief_summary>
	<brief_title>Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Alphafeto protein &gt; 400 ng / mL or prior ultrasound with mass suspicious for hepatic malignancy or. clinical risk of hepatocellular carcinoma or prior multidetector CT with mass suspicious for possible hepatocellular carcinoma Glomerulofiltration rate &lt; 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study Previous diagnosis of hepatic malignancy Any conditions that would discount the ability to have an MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HCC</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>MRI</keyword>
	<keyword>Liver</keyword>
</DOC>